562 related articles for article (PubMed ID: 20171075)
1. Myeloid-derived suppressor cell heterogeneity and subset definition.
Peranzoni E; Zilio S; Marigo I; Dolcetti L; Zanovello P; Mandruzzato S; Bronte V
Curr Opin Immunol; 2010 Apr; 22(2):238-44. PubMed ID: 20171075
[TBL] [Abstract][Full Text] [Related]
2. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF.
Dolcetti L; Peranzoni E; Ugel S; Marigo I; Fernandez Gomez A; Mesa C; Geilich M; Winkels G; Traggiai E; Casati A; Grassi F; Bronte V
Eur J Immunol; 2010 Jan; 40(1):22-35. PubMed ID: 19941314
[TBL] [Abstract][Full Text] [Related]
3. CD49d is a new marker for distinct myeloid-derived suppressor cell subpopulations in mice.
Haile LA; Gamrekelashvili J; Manns MP; Korangy F; Greten TF
J Immunol; 2010 Jul; 185(1):203-10. PubMed ID: 20525890
[TBL] [Abstract][Full Text] [Related]
4. Myeloid-derived suppressor cell activation by combined LPS and IFN-gamma treatment impairs DC development.
Greifenberg V; Ribechini E; Rössner S; Lutz MB
Eur J Immunol; 2009 Oct; 39(10):2865-76. PubMed ID: 19637228
[TBL] [Abstract][Full Text] [Related]
5. Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway.
Haile LA; von Wasielewski R; Gamrekelashvili J; Krüger C; Bachmann O; Westendorf AM; Buer J; Liblau R; Manns MP; Korangy F; Greten TF
Gastroenterology; 2008 Sep; 135(3):871-81, 881.e1-5. PubMed ID: 18674538
[TBL] [Abstract][Full Text] [Related]
6. CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells.
Yang R; Cai Z; Zhang Y; Yutzy WH; Roby KF; Roden RB
Cancer Res; 2006 Jul; 66(13):6807-15. PubMed ID: 16818658
[TBL] [Abstract][Full Text] [Related]
7. Myeloid derived suppressor cells and their role in tolerance induction in cancer.
Fujimura T; Mahnke K; Enk AH
J Dermatol Sci; 2010 Jul; 59(1):1-6. PubMed ID: 20570112
[TBL] [Abstract][Full Text] [Related]
8. IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients.
Mandruzzato S; Solito S; Falisi E; Francescato S; Chiarion-Sileni V; Mocellin S; Zanon A; Rossi CR; Nitti D; Bronte V; Zanovello P
J Immunol; 2009 May; 182(10):6562-8. PubMed ID: 19414811
[TBL] [Abstract][Full Text] [Related]
9. Myeloid-derived suppressor cells--their role in haemato-oncological malignancies and other cancers and possible implications for therapy.
Tadmor T; Attias D; Polliack A
Br J Haematol; 2011 Jun; 153(5):557-67. PubMed ID: 21477210
[TBL] [Abstract][Full Text] [Related]
10. Contribution of myeloid-derived suppressor cells to tumor-induced immune suppression, angiogenesis, invasion and metastasis.
Ye XZ; Yu SC; Bian XW
J Genet Genomics; 2010 Jul; 37(7):423-30. PubMed ID: 20659706
[TBL] [Abstract][Full Text] [Related]
11. Analysis of splenic Gr-1int immature myeloid cells in tumor-bearing mice.
Yamamoto Y; Ishigaki H; Ishida H; Itoh Y; Noda Y; Ogasawara K
Microbiol Immunol; 2008 Jan; 52(1):47-53. PubMed ID: 18352913
[TBL] [Abstract][Full Text] [Related]
12. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells.
Marigo I; Dolcetti L; Serafini P; Zanovello P; Bronte V
Immunol Rev; 2008 Apr; 222():162-79. PubMed ID: 18364001
[TBL] [Abstract][Full Text] [Related]
13. Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties.
Brandau S; Trellakis S; Bruderek K; Schmaltz D; Steller G; Elian M; Suttmann H; Schenck M; Welling J; Zabel P; Lang S
J Leukoc Biol; 2011 Feb; 89(2):311-7. PubMed ID: 21106641
[TBL] [Abstract][Full Text] [Related]
14. Myeloid cell diversification and complexity: an old concept with new turns in oncology.
Chioda M; Peranzoni E; Desantis G; Papalini F; Falisi E; Solito S; Mandruzzato S; Bronte V
Cancer Metastasis Rev; 2011 Mar; 30(1):27-43. PubMed ID: 21267772
[TBL] [Abstract][Full Text] [Related]
15. Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells.
Donkor MK; Lahue E; Hoke TA; Shafer LR; Coskun U; Solheim JC; Gulen D; Bishay J; Talmadge JE
Int Immunopharmacol; 2009 Jul; 9(7-8):937-48. PubMed ID: 19362167
[TBL] [Abstract][Full Text] [Related]
16. The growing diversity and spectrum of action of myeloid-derived suppressor cells.
Mantovani A
Eur J Immunol; 2010 Dec; 40(12):3317-20. PubMed ID: 21110315
[TBL] [Abstract][Full Text] [Related]
17. Myeloid-derived suppressor cell role in tumor-related inflammation.
Dolcetti L; Marigo I; Mantelli B; Peranzoni E; Zanovello P; Bronte V
Cancer Lett; 2008 Aug; 267(2):216-25. PubMed ID: 18433992
[TBL] [Abstract][Full Text] [Related]
18. Highlights on molecular mechanisms of MDSC-mediated immune suppression: paving the way for new working hypotheses.
Solito S; Pinton L; Damuzzo V; Mandruzzato S
Immunol Invest; 2012; 41(6-7):722-37. PubMed ID: 23017143
[TBL] [Abstract][Full Text] [Related]
19. Immunosuppressive myeloid-derived suppressor cells can be converted into immunogenic APCs with the help of activated NKT cells: an alternative cell-based antitumor vaccine.
Ko HJ; Lee JM; Kim YJ; Kim YS; Lee KA; Kang CY
J Immunol; 2009 Feb; 182(4):1818-28. PubMed ID: 19201833
[TBL] [Abstract][Full Text] [Related]
20. Transcription factors in myeloid-derived suppressor cell recruitment and function.
Sonda N; Chioda M; Zilio S; Simonato F; Bronte V
Curr Opin Immunol; 2011 Apr; 23(2):279-85. PubMed ID: 21227670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
